Results 271 to 280 of about 1,660,326 (362)

A Catalog of Patent Applications Published in 2024 Related to Ophthalmology and Vision Science. [PDF]

Transl Vis Sci Technol
Stern G, Stern B, Mallett JJ, Chuck RS.
europepmc   +1 more source

Economics of Our Patent System

, 1925
Lawrence K. Frank, Floyd L. Vaughan
openalex   +2 more sources

Patent Urachus and Associated Comorbidities in 101 Newborn Foals: A Retrospective Study. [PDF]

Vet Med Sci
Bernick A, Krohn J, Wehrend A.
europepmc   +1 more source

Loss of proton‐sensing GPR4 reduces tumor progression in mouse models of colon cancer

Molecular Oncology, EarlyView.
G protein‐coupled receptor 4 (GPR4) is a pH‐sensing receptor activated by acidic pH. GPR4 expression is increased in patients with inflammatory bowel disease who are at high risk of developing colorectal cancer. In mouse models, loss of GPR4 attenuated tumor progression. This correlated with increased IL2 and natural killer cell activity.
Leonie Perren, Moana Busch, Pedro A. Ruiz, Ermanno Malagola, Valeria Baumeler, Federica Foti, Adelina Gross, Tobias Grütter, Hendrik Edel, Cordelia Schuler, Kristina Handler, Glenn De Lange, Isabelle C. Arnold, Cheryl de Vallière, Klaus Seuwen, Martin Hausmann, Gerhard Rogler   +16 more
wiley   +1 more source

A multidimensional research productivity dataset of 21^st-century Nobel Laureates in physiology or medicine. [PDF]

Sci Data
Burnett WJ, Balas EA.
europepmc   +1 more source

Section 271(b) of the Patent Act of 1952: Confusion Codified

, 1956

openalex   +2 more sources

TRPM8 levels determine tumor vulnerability to channel agonists

Molecular Oncology, EarlyView.
TRPM8 is a Ca2+ permissive channel. Regardless of the amount of its transcript, high levels of TRPM8 protein mark different tumors, including prostate, breast, colorectal, and lung carcinomas. Targeting TRPM8 with channel agonists stimulates inward calcium currents followed by emptying of cytosolic Ca2+ stores in cancer cells.
Alessandro Alaimo, Francesco Giuseppe Carbone, Kristi Buzo, Nicole Annesi, Sacha Genovesi, Annalisa Lorenzato, Karen Widmann, Michela Libergoli, Elisa Marmocchi, Giovanni Bertalot, Alberto Brolese, Mauro Giulio Papotti, Luca Molinaro, Orazio Caffo, Mattia Barbareschi, Alberto Bardelli, Alessandro Romanel, Sabrina Arena, Andrea Lunardi   +18 more
wiley   +1 more source

International comparison of generic competition, prices, and usage trends: South Korea and G20 countries. [PDF]

Front Public Health
Lee DH, Kim JA, Lim KM, Jung JW, Park SM, Jang YA, Lee JH.   +6 more
europepmc   +1 more source

THE SURGICAL TREATMENT OF PATENT DUCTUS ARTERIOSUS

, 1945
M Servelle
openalex   +2 more sources

The anticancer effect of the HDAC inhibitor belinostat is enhanced by inhibitors of Bcl‐xL or Mcl‐1 in ovarian cancer

Molecular Oncology, EarlyView.
The pan‐HDAC inhibitor belinostat increases the expression of the pro‐apoptotic proteins Bim, Puma, and Noxa and induces apoptosis in ovarian cancer cell lines and patient‐derived tumor organoids when used at high concentrations. Moreover, inhibiting the anti‐apoptotic proteins Bcl‐xL or Mcl‐1 sensitizes these preclinical models to the cytotoxic effect
Cécilia Thomine, Sterenn Guillemot, Louis‐Bastien Weiswald, Romane Florent, Edwige Abeilard, Florence Giffard, Emilie Brotin, Mélanie Briand, Enora Dolivet, Laurent Poulain, Marie Villedieu   +10 more
wiley   +1 more source